Molecular imaging firm Blue Earth Diagnostics said that its Axumin (fluciclovine F-18) PET imaging agent has been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer.
The updated EAU prostate cancer guidelines indicate that Axumin is the only prostate cancer-specific radiotracer that is commercially available on a widespread basis, according to the company. Axumin is approved in the European Union with PET imaging to detect and localize recurrent prostate cancer, and it is commercially available in Italy, France, Norway, the Czech Republic, the Netherlands, the U.K., and Austria.
Blue Earth said it plans to release the radiopharmaceutical in additional European countries soon.
